AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofacitinib 5 mg twice daily
Description: use of JAK inhibitor at full dose until the end of the protocol
Study NCT06687551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Upadacitinib 15 MG
Description: use of JAK inhibitor at full dose until the end of the protocol
Study NCT06688721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Driving a bus equipped with EDA
Description: Eco-driving assistance (EDA) systems is a technology integrated into vehicles that helps drivers to optimize fuel efficiency and reduce emissions by providing real-time feedback and guidance on driving behaviors. The system typically analyzes several driving behaviours that are measured using different captors and sensors. These systems aim to reduce the overall carbon footprint of driving, leading to cost savings for the public transport company and reduced environmental impact.
Study NCT06691802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shu Fei Tie
Description: Optimize the extraction process and matrix formulation, and combine the use of traditional Chinese medicine volatile oil and chemical transdermal enhancers to develop adermal patch（Shu Fei Tie）
Study NCT06691802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shu Fei Tie placebo
Description: Shu Fei Tie Placebos are made using substances without active drug ingredients, following the same preparation procedures
Study NCT06686004 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrots
Description: Detection of polyacetylene and carotenoids in human biofluids
Study NCT06691295 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: This study aims to explore transdiagnostic psychological processes (PP) via the administration of self-reported scales and questionnaires, in a population of newly diagnosed FND patients, prior to any therapeutic management.~The main objective is to describe the psychometric properties (scores on tools measuring psychological processes) of NFT patients (presenting the main phenotypes; sensitivo-motor; and seizures and discomfort).
Study NCT06687213 — intervention group
Intervention type: BEHAVIORAL
Intervention: Smoking cessation counselling group
Description: Case group will be counseled to cessate smoking and will be followed up with HbA1c
Study NCT06690021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Thoracolumbar Interfascial Plane Block using Bupivacaine and dexmedetomidine
Study NCT05497960 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Vivo workout
Description: 2 days a week for 12 weeks of a live, interactive virtual strength training program. Each class is 45 minutes long and lead by a certified trainer.
Study NCT06695364 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: survey study
Description: Not all classes were included in the study
Study NCT06694077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexamethasone
Description: bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.
Study NCT06694077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine only
Description: bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline
Study NCT06694987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Physician Health Worker
Description: NPHW will aid participants in accessing a family doctor if required. The family doctor will receive a letter from the study, with suggested medication, based on the HOPE-4 algorithm. The family doctor may decide not to prescribe the recommended treatment or give another treatment (medication). In such case, the participant will still be part of the study and family physician's decision and reason why will be recorded. Follow-up will occur as per the visit schedule. All participants will attend a 20-minute follow-up visits in person at 0, 6 and 12 months, and via telephone at 3 and 9 months.~Participants will be assessed to determine if: i. the patient was assessed by their family physician, ii. the family doctor initiated recommended medication treatment(s), iii. they are adhering to the medications as prescribed, iv. they implemented what the NPHW has recommended about dietary and lifestyle changes, using the specific, measurable, achivable, relevant, time-bound (SMART) for goals.
Study NCT06694181 — intervention group
Intervention type: OTHER
Intervention: AI-PERSONALIZED CLINICAL DECISION SUPPORT
Description: AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
Study NCT06695208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: biodentine used in socket preservation
Study NCT06695208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: biodentine used in socket preservation
Study NCT06691490 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Sham
Description: cTBS over SMA and cTBS over precuneus (control site)
Study NCT06691490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation Sham
Description: cTBS over SMA and cTBS over precuneus (control site)
Study NCT06690008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental group
Description: SDF application
Study NCT06690008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: SDF application
Study NCT06688903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based diabetes management and community-based health coaching
Description: All participants will use the EMPOWER+ app and a Fitbit wearable. They will also received community-based health coaching and/or other prescribed structured programmes.
Study NCT06688110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gixam System
Description: Jubaan's Gixam System is designed to predict the likelihood of colorectal adenomas or SSL by using white light in the 400 to 720 nm range to capture ultra-high-definition images of the of the tongue and analyzing the spectral signature of the oral microbiome to predict the presence of colorectal adenomas or SSL with help of artificial intelligence (AI).
Study NCT06686095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Adductor canal block
Description: Adductor canal block procedure: The patient will be informed about the technique and consent will be obtained. The patient's hip will be slightly externally rotated, and an ultrasonography linear probe will be placed on the medial thigh, at the midpoint of the patella and vastus medialis. After locating the femoral artery at approximately 3-4 cm depth, if not visible, the artery can be traced distally from the inguinal region using Doppler mode. Once the vastus medialis and sartorius muscles are identified, the superficial femoral artery is centered at the midpoint of the sartorius muscle. The adductor canal roof, along with the saphenous and vastus medialis nerves, appears as hyperechoic structures. A needle is inserted in-plane, advancing toward the anterolateral femoral artery aspect, and 5-20 mL of LA is injected.
Study NCT06686095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group Genicular Nerve Block
Description: Genicular Nerve Block: The patient is informed and consent is obtained. With a pillow in the popliteal fossa, the knee is slightly flexed. For the superior lateral genicular nerve, a linear USG probe is positioned on the lateral femoral epicondyle, moving proximally to visualize the bone metaphysis. The superolateral artery is seen between the vastus lateralis fascia and the femur. Using in-plane or out-of-plane technique, the needle is guided to the bone, and 4-5 mL of LA is injected. For the superior medial nerve, the probe is placed on the medial epicondyle and moved proximally to visualize the bone near the adductor tubercle. The artery lies between the femur and vastus medialis fascia. For the inferomedial artery, the probe is placed on the tibial medial condyle, moving distally. A negative aspiration test is conducted before each LA injection.
Study NCT06274138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: haptonomy
Description: Pregnant women in the intervention group will complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. Information will be given that Haptonomy will consist of five sessions. Haptonomy will be applied by the researcher together with the partner. Each session will last for 40 minutes. The effectiveness and continuity of sessions will be planned between 3 to 7 days. One week after completing the five sessions of haptonomy, pregnant women will again complete the Prenatal Attachment Scale and Marital Adjustment Scale, and fathers will complete the Antenatal Father Attachment Scale and Marital Adjustment Scale through face-to-face interviews. The completion of the scales will take approximately 10-15 minutes.
Study NCT06119698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GetActive+
Description: This is a 10-week group mind body program focused on improving self-reported physical activity, performance-based physical activity, and ambulatory step count by combining mind body skills tailored for individuals with chronic pain, with gradual increase in walking using quota based pacing and goal setting, adapted specifically for older adults from a medically underserved location.
Study NCT06213012 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Spinal cord Stimulation
Description: Delivered using a constant-current stimulator
Study NCT06213012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Spinal cord Stimulation
Description: Delivered using a constant-current stimulator
Study NCT06213012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Stimulation (ESS)
Description: The device used for ESS, the CoverEdgeX 32 Surgical Lead system (Boston Scientific, USA), is a device approved by the FDA used in the treatment of severe pain and is approved for individuals to manage chronic pain when other treatments have not been effective.~If you are in the ESS group, you will have surgery to have the stimulator placed and the stimulator will be removed at an office visit towards the end of the study.
Study NCT05666700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination Product: JNJ-68284528 (Cilta-cel) & 64Cu SPION dual PET-MR imaging agent
Description: Cilta-cel is a cellular immunotherapy derived from autologous CD3+ T-cells that have undergone ex vivo modification to target B-Cell Maturation Antigen (BCMA) on the surface of plasma cells. Cilta-cel will be administered as two IV infusions, ≥70% unlabeled and ≤30% labelled. The dose will be based on the patient's weight (kg) at apheresis
Study NCT06055959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Description: Zilucoplan will be administered subcutaneously to pediatric study participants.
Study NCT05812144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Remote monitoring program
Description: Remote program is composed of some questionnaires and physical exercises performed at home and at hospital (depending on the concerned visit)
Study NCT04877704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symprove (probiotic)
Description: Symprove's unique water-based formula is packed full of live, active bacteria. It is a probiotic, not a drug.
Study NCT04877704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to Symprove probiotic
Study NCT06464679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR NK cells
Description: Patients will receive Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of CD19 CAR NK cells will infused using the dose-escalation strategy.
Study NCT05480774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KRG hard capsule
Description: Each subject was given orally 2 KRG hard capsules/day for 12 weeks
Study NCT05480774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hard capsule
Description: Each subject was given orally 2 placebo hard capsules/day for 12 weeks
Study NCT06274346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiangular Isometric exercise
Description: already were described in arm descriptions
Study NCT06274346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiangular Isometric exercise
Description: already were described in arm descriptions
Study NCT06274346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiangular Isometric exercise
Description: already were described in arm descriptions
Study NCT05331989 — intervention group
Intervention type: OTHER
Intervention: patient group/ healthy group
Description: Cranio- Cervical Flexion Test, cervical mobility, Pressure Pain Threshold,Functional evaluation of the temporomandibular joint,Pittsburg Sleep Quality Index
Study NCT04575662 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STAR Treatment
Description: Radiation therapy that delivers non-invasive, image-guided, precise high-dose of radiation to targets reducing dose exposure to adjacent normal tissue and minimizing the treatment toxicity.
Study NCT05280015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: microbiotherapy (GynMDD)
Description: multi-target microbiotherapy add-on venlafaxine
Study NCT05280015 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo add-on venlafaxine
Study NCT04391868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viagra Tablet
Description: 50 mg tablet on Day 1 of each period
Study NCT04391868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate ODF
Description: 50 mg ODF on Day 1 of each period
Study NCT06298292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Zero minis (range of protein substitutes in tablet form)
Description: Intervention: range of protein substitute tablets. Subjects who currently take a protein substitute for the dietary management of either tyrosinaemias or alkaptonuria, homocystinuria, or MSUD will be recruited. Subjects will take the study product for 7 days. Daily questionnaires will be completed (ease of preparation,administration; any problems or gastrointestinal effects). Subjects will replace some or their entire usual protein substitute with the new product suitable for their diagnosed rare metabolic disease. The amount of tablets prescribed will be calculated to provide the same amount of protein as their usual protein substitute. Additional questions at the beginning and end of the study will record information on organoleptic properties, presentation and packaging of the product. Routine weekly blood samples will be collected and analysed for amino acids typically for the metabolic control of the individual specified metabolic disorders as is usual clinical practice.
Study NCT06512766 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Patients in this group were treated with hydroxychloroquine (HCQ), a systemic medication commonly used as a first-line treatment due to its ease of use and established safety profile. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study NCT06512766 — intervention group
Intervention type: DRUG
Intervention: Methotrexate
Description: This group consists of patients treated with methotrexate (MTX), a systemic medication often used as a second-line treatment for its effectiveness in reducing inflammation and controlling autoimmune responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study NCT06512766 — intervention group
Intervention type: DRUG
Intervention: Cyclosporine A
Description: Patients in this group were treated with cyclosporine A (CsA), a potent immunosuppressive agent used for its effectiveness in controlling severe inflammatory responses. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study NCT06512766 — intervention group
Intervention type: DRUG
Intervention: Retinoids
Description: This cohort includes patients treated with retinoids, which are used for their ability to modulate cell growth and differentiation. Due to the retrospective nature of the study, the dosage form, dosage, frequency, and duration of treatments varied among patients.
Study NCT06318923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Socio-demographic questionnaire, moral judgment task, cognitive tests, psychoaffective assessment
Description: The demographic questionnaire collects demographic information: gender, age, level of education, laterality, history of psychiatric or neurological disorders.~The moral judgment task consists in completing 20 vignettes of moral dilemmas. Cognitive disorders will be assessed using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. If the patient has taken the BICAMS battery recently (less than 6 months), and with no change in pathology since then, the results of these tests will be used in this study.~Affective disorders will be assessed using the following tests:~* The Beck Depression Inventory-Fast Screen (BDI-FS) to assess the level of depression,~* State trait anxiety inventory-Y (STAI-Y) to assess anxiety,~* Toronto Alexithymia Scale-20 (TAS-20)to assess alexithymia,~* The Empathy Quotient-8 (EQ-8) to assess participants' level of empathy,~* The Dot Probe Task to assess participants' emotional information processing style.
Study NCT06318923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MS questionnaire
Description: This questionnaire collects key information on the participant's pathology: clinical form, date of first symptoms, diagnosis, last attack, as well as latest EDSS and functional scores.
Study NCT06318923 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MONTREAL COGNITIVE ASSESSMENT (MoCA) test
Description: The MoCA is a screening tool for neurocognitive impairment, designed primarily to detect milder impairment. The MoCA is a short-answer questionnaire that includes a number of tasks to be completed by the individual. The items assessed are grouped into six subsections: short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space. The tests proposed are often more complex than those found in the mini-mental state examination (MMSE).
Study NCT05757999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: A magnesium sulphate infusion (60 mg kg-1, total volume 100 ml, infusion rate 10 ml min-1) will be administered to patients 10 min. before induction of anesthesia.
Study NCT05757999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The patients will be pretreated with an intravenous 0.9% saline infusion (total volume 100 ml, infusion rate 10 ml min-1) 10 min before induction of anesthesia.
Study NCT06686095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group IPACK Block
Description: IPACK Block: Before the procedure, the patient is informed about the technique and written consent is obtained from the patient. The patient lies in the prone position. The linear USG probe is placed approximately 2-3 cm above the popliteal fossa and scanned distally to identify the femoral shaft and popliteal artery. If the femoral condyles are initially visualized, the probe is moved until the condyles disappear and the femoral shaft is identified as a straight line and hyperechoic. Color doppler can be used to identify the popliteal vessels. The peripheral block needle is advanced between the femoral shaft and the popliteal artery. After negative aspiration control, 15-20 mL of LA medication is injected here.
Study NCT06686836 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift augmentation with bone substitute (Bio-Oss)
Description: A maxillary sinus lift augmentation was performed with a lateral window approach that was filled with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®).At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically.
Study NCT06686836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open sinus lift surgery lift using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®(Geistlich AG, Wolhusen, Switzerland)) - L-PRF Block
Description: A maxillary sinus lift augmentation was performed with a lateral window approach that was filled using Platelet- and leukocyte-rich fibrin (L-PRF) mixed with a bone substitute (Bio-Oss®) and covered with a collagen membrane (Bio-Guide®) (L-PRF block).~L-PRF block will be performed as described by Cortellini et al. 2018. L-PRF membranes are cut into small pieces and mixed with Bio-Oss® at a ratio of 2 membranes / 0.5 g biomaterial. Pieces of the block will be removed and compacted in the sinus cavity until it is filled.~At 4 months after sinus lift, a biopsy was taken and implants (Starumann®) were placed with submerged healing. After 6 months, the second surgical phase was performed and another biopsy was taken. The bone samples collected were analyzed histologically and histomorphometrically.
Study NCT06691399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral care
Description: Oral care done twice daily with chlorhexidine oral care solution (concentration 1.2%)
Study NCT06691399 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral care
Description: Oral care done twice daily with chlorhexidine oral care solution (concentration 1.2%)